Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded at $10.84 at last check on Monday, May 03, made an upward move of 1.31% on its previous day’s price.
Looking at the stock we see that its previous close was $10.7 and the beta (5Y monthly) reads 1.45 with the day’s price range being $10.71 – 10.88. The company has a trailing 12-month PE ratio of 0. In terms of its 52-week price range, TEVA has a high of $13.3 and a low of $8.44. The company’s stock has gained about -7.28% over that past 30 days.
Teva Pharmaceutical Industries Limited has a market cap of $11.48 Billion and is expected to release its quarterly earnings report in June. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the TEVA stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of $0.59, with the EPS growth for the year raised at $2.61 for 2021 and $2.74 for next year. These figures represent 0.02% and 0.05% growth in EPS for the two years respectively.
On the other hand, looking at the outlook for the TEVA stock, short term indicators assign the stock an average of Hold, while medium term indicators assign it an average of Hold. Long term indicators on average place the stock in the category of 50% Buy.
Based on estimates by 22 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 15 have rated the Teva Pharmaceutical Industries Limited (TEVA) stock as a Hold, while 4 rate it as a Buy. 1 analyst(s) rate it as outperform while 1 of them rated it as underperform, whereas 1 suggest the stock as a Sell. The stock has an overall rating of Hold and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the TEVA stock currently stands at 0, and the most recent price level today is 1.29% off its SMA20 and -1.07% from its 50-day simple moving average. The RSI (14) is pointing at 51.65 while the volatility over the past week is 3.32% and drops to 2.78% over the past one month. The beta value is 1.45, while the average true range (ATR) is currently pointing at 0.34. The average price target for the stock over the next 12 months is $12.06, with the estimates having a low of $9 and a high of $17. These price ends are -16.97% and +56.83% off the today’s price level respectively, although investors could be excited at the prospect of a +10.7% if the TEVA share price touches on the median price of $12.
Let’s briefly compare Teva Pharmaceutical Industries Limited (TEVA) stock to its peers. We find that today’s price change of +1.31% and -0.37% over the past 12 months for TEVA competes that of Dr. Reddy's Laboratories Ltd (RDY), which has seen its stock price rise 1.7% in the latest trading session and is +34.83% over the last one year. Another of its peers Bausch Health Companies Inc (BHC) has dropped -1.74% today, and was +77.54% up over the past year, while Bridgebio Pharma Inc (BBIO) is also up 1.31% yet, while its price remains in the red at -0.37% over the same period. Teva Pharmaceutical Industries Limited has a P/E ratio of 0 compared to Dr. Reddy's Laboratories Ltd’s 39.99 and Bausch Health Companies Inc’s 0. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.36% and 0.83%, respectively, in early deals.
Coming back to Teva Pharmaceutical Industries Limited (NYSE:TEVA), we note that the average 3-month trading volume was 9.82 Million, while that of the preceding 10-day period stands at 4.06 Million. Current shares outstanding are 1.1 Billion.
According to data from Thomson Reuters, insiders hold 0.78% of the company’s shares while institutions hold 52.18%. The data shows that short shares as of April 14, 2021, stood at 29.83 Million at a short ratio of 4.67. This represents a 2.71% short interest in shares outstanding on April 14, 2021. Shares short dropped in April from the previous month at 36.37 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock +10.88% up in year-to-date price movement.